Complete Sequencing and mRNA Expression Analysis of the MEN-I Gene in Adrenal Myelolipoma

Schulte, Klaus–Martin; Heinze, M.; Mengel, Martina; Scheuring, Sibylle; Köhrer, Karl; Röher, H.-D.

doi:10.1055/s-2007-978616

Cited by 13 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Due to the association with other endocrine tumors some authors proposed that adrenal myelolipoma may be justified by defects of the gene responsible for multiple endocrine neoplasia type I (MEN I), but molecular studies do not support this hypothesis 10 . Moreover, others consider myelolipoma more likely a hamartoma than a true neoplasm, while another opinion is that excess hormone production by adrenocortical neoplasms can be considered one of the induction regulatory mechanisms of myelolipomatous foci 6 …”

Section: Discussionmentioning

confidence: 99%

Adrenal myelolipoma associated with adenoma

et al. 2004

View full text Add to dashboard Cite

The association of an adrenal myelolipoma with a non-functioning adenoma is very rare. Herein, we report on such a case in an asymptomatic 64-year-old woman. To the best of our knowledge, there is only one other case of non-functioning adrenocortical adenoma associated with myelolipoma in the same gland. Furthermore, only two other adenomas (mineral corticoids and corticosteroid producing tumors) associated with myelolipomas have been reported, and both myelolipomas were less than 1 cm in size. In conclusion, the 8.5 cm myelolipoma in our case is the largest compared with the three previously reported ones.

show abstract

Section: Discussionmentioning

confidence: 99%

Adrenal myelolipoma associated with adenoma

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Although MEN-1 association has been suggested in some of the reported cases, complete DNA sequencing yielded no hint that defects of the MEN-1 gene is responsible for the formation of AML. [ 4 ] Low levels of p53 proteins in AML suggest the role of tumor suppressor gene in the tumorogenesis of AML. [ 5 ]…”

Section: Introductionmentioning

confidence: 99%

Adrenal myelolipoma: Controversies in its management

Shenoy¹,

Thota²,

Shankar³

et al. 2015

Indian J Urol

View full text Add to dashboard Cite

Adrenal myelolipomas (AMLs) are rare, benign neoplasms of the adrenal gland with varied clinical presentations. The rarity of these tumors precludes any case-controlled or randomized study into their management. The available literature is limited to case reports and short series from referral centers. This review is an effort to put the available literature into perspective such that clinical decision making can be done with some clarity. The PubMed and Cochrane databases were searched with key words Adrenal Myelolipoma, Adrenal Incidentaloma (AI) and Adrenal Collision Tumor (ACT). From over 1300 search results, 547 relevant publications dating from 1954 to 2014 were reviewed. Details of about 1231 AMLs in the indexed literature were analyzed. Increasing usage of imaging studies has significantly increased the discovery of AMLs. Although AMLs are benign tumors, those measuring larger than 6 cm are prone to rupture and hemorrhage. Thorough endocrine work-up may benefit a selected group of patients, especially those who are hypertensive, diabetic/pre-diabetic, young patients (<50 years) and those with bilateral AML. Regular observation is needed for AML patients who are being treated non-operatively, as many of them may require surgery during follow-up. Although the AACE/AAES guidelines for AI (2009) exclude AML from mandatory metabolic work-up for a newly discovered AI, we feel that a significant number of patients with AML would benefit from metabolic work-up. In the literature, endocrine dysfunction in AML is 7% as compared with 11% in AI. Endocrine dysfunction in AML is probably underdiagnosed.

show abstract

“…Although multiple endocrine neoplasia type 1 (MEN-1) association has been suggested in some of the reported cases, complete DNA sequencing yielded no hint that defects of the MEN-1 gene is responsible for the formation of AML. 11 Low levels of p53 proteins in AML suggest the role of tumor suppressor gene in its tumorigenesis. 12…”

Section: Discussionmentioning

confidence: 99%

A rare case of adrenal collision tumor: Myelolipoma and schwannoma in the adrenal gland

Gomez

Mehta

2020

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

Adrenal collision tumors refer to coexistence of two adjacent, but histologically distinct, neoplasms involving the adrenal gland without histologic admixture at the interface. Myelolipoma is a rare but benign neoplasm. As its name implies, displays both mature adipose tissue and hematopoietic elements. These are usually unilateral and asymptomatic. Schwannomas, tumors derived from the peripheral nerve sheath, are also uncommon lesions in the adrenal gland. Here, we present a rare case of a 65-year-old male with clinical history of abdominal aortic aneurysm who was found to have a 13-cm “incidentaloma” by interventional radiologist during his aortic endograft control. Giving the size of the mass, team decided to excise it, and histopathological examination was performed. While most incidentally discovered adrenal tumors are benign, surgical excision is recommended in large lesions to exclude malignancy, avoid hemorrhage, and/or acute adrenal insufficiency. Given the rarity of such entity, its clinical course and prognosis remains unclear.

show abstract

Complete Sequencing and mRNA Expression Analysis of the MEN-I Gene in Adrenal Myelolipoma

Cited by 13 publications

References 10 publications

Adrenal myelolipoma associated with adenoma

Adrenal myelolipoma associated with adenoma

Adrenal myelolipoma: Controversies in its management

A rare case of adrenal collision tumor: Myelolipoma and schwannoma in the adrenal gland

Contact Info

Product

Resources

About